CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2019—Bühlmann Laboratories received FDA 510(k) clearance for its Bühlmann fCAL turbo in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The test aids in the diagnosis of inflammatory bowel disease, specifically Crohns disease and ulcerative colitis, and in the differentiation of IBD from irritable bowel syndrome, in conjunction with other laboratory and clinical findings.
Pages: 1 2